Company intelligence / Profile preview

Character Biosciences

Jersey City, New Jersey, United Statescharacterbio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Character Biosciences has raised $93 million in Series B funding to advance its lead candidates CTX114 and CTX203 into clinical trials. The company has partnered with over 150 ophthalmology centers and collected data from over 6,500 patients to reclassify AMD into genetically-defined subtypes.

Therapeutic areas: Ophthalmology
Industry: Biotech

Drug pipeline

3 assets

CTX020

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Bausch + Lomb (announced January 2025)

Beyond the preview

Go deeper on Character Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Character Biosciences.

Explore the full profile